Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Osteoporos Int. 2010 Jan;21(1):167-77. doi: 10.1007/s00198-009-0953-7. Epub 2009 May 13.
The purpose of the study was to test the hypothesis that the reduction in fractures with hormone therapy (HT) is greater in women with lower estradiol levels.
We conducted a nested case-control study within the Women's Health Initiative HT Trials. The sample included 231 hip fracture case-control pairs and a random sample of 519 all fracture case-control pairs. Cases and controls were matched for age, ethnicity, randomization date, fracture history, and hysterectomy status. Hormones were measured prior to randomization. Incident cases of fracture were identified over an average follow-up of 6.53 years.
There was no evidence that the effect of HT on fracture differed by baseline estradiol (E2) or sex hormone binding globulin (SHBG). Across all quartiles of E2 and SHBG, women randomized to HT had about a 50% lower risk of fracture, including hip fracture, compared to placebo.
The effect of HT on fracture reduction is independent of estradiol and SHBG levels.
本研究的目的是检验激素治疗（HT）降低骨折风险的效果在雌二醇水平较低的女性中更大的假设。
我们在妇女健康倡议 HT 试验中进行了一项嵌套病例对照研究。该样本包括 231 对髋部骨折病例对照和 519 对所有骨折病例对照的随机样本。病例和对照在年龄、种族、随机日期、骨折史和子宫切除术状态方面进行了匹配。激素在随机分组前进行了测量。平均随访 6.53 年后确定了骨折的发生情况。
没有证据表明 HT 对骨折的影响与基线雌二醇（E2）或性激素结合球蛋白（SHBG）有关。在 E2 和 SHBG 的所有四分位数中，与安慰剂相比，接受 HT 治疗的女性骨折风险降低了约 50%，包括髋部骨折。
HT 对骨折减少的影响与雌二醇和 SHBG 水平无关。
